Shire Plc Ads (SHPG) 194.12 $SHPG
Shire Recommends ADS Holders Reject TRC Capital's "Mini-Tender Offer"
PR Newswire - Fri Jul 29, 3:20PM CDT
Shire plc (LSE: SHP) (NASDAQ: SHPG) has been notified of an unsolicited "mini-tender" offer made by TRC Capital Corporation ("TRC Capital"
to purchase up to 1,000,000 American Depositary Shares ("ADSs" of Shire, each representing three ordinary shares of Shire, at a price of $182.75 per ADS in cash. The offer is for approximately 0.33 percent of the outstanding ordinary shares of Shire.
SHPG: 194.12 (+2.69)
Shire's SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
PR Newswire Europe - Fri Jul 29, 6:01AM CDT
LEXINGTON, Massachusetts, July 29, 2016 /PRNewswire/ --
SHPG: 194.12 (+2.69)
ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia
PR Newswire - Tue Jul 26, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) will present additional data on the clinical experience of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant Factor VIII (rFVIII) replacement for hemophilia A, during the International Congress of the World Federation of Hemophilia (WFH) in Orlando, Florida. Throughout the Congress, Shire will present more than a dozen scientific updates on the company's broad portfolio of treatments for bleeding disorders, including ADYNOVATE.
SHPG: 194.12 (+2.69)
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
PR Newswire Europe - Mon Jul 25, 1:01AM CDT
ZUG, Switzerland, July 25, 2016 /PRNewswire/ --
MACK: 5.80 (+0.19), SHPG: 194.12 (+2.69)
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union
PR Newswire - Mon Jul 25, 1:01AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for ONIVYDE® (irinotecan liposome injection), also known as "nal-IRI", in combination with fluorouracil (5-FU) and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma who have progressed after gemcitabine-based therapy. The CHMP positive opinion for ONIVYDE will now be reviewed by the European Commission (EC) for marketing authorization. Shire plc (LSE: SHP, NASDAQ: SHPG) is responsible for the development and commercialization of ONIVYDE outside of the United States and Taiwan pursuant to an exclusive licensing agreement with Merrimack.
MACK: 5.80 (+0.19), SHPG: 194.12 (+2.69)
Shire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of the World Federation of Hemophilia
PR Newswire - Tue Jul 19, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG), following its combination with Baxalta in June, will affirm its commitment to advancing patient care and scientific innovation at the International Congress of the World Federation of Hemophilia (WFH) in Orlando, Florida, July 24-28, 2016. Data at the Congress this year will showcase the company's robust hematology portfolio and pipeline.
SHPG: 194.12 (+2.69)
Coverage Initiated on Select Healthcare Stocks
ACCESSWIRE - Thu Jul 14, 8:17AM CDT
LONDON, UK / ACCESSWIRE / July 14, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Healthcare sector. Companies recently under review include Shire, Novartis, Anavex Life Sciences, and Impax Laboratories. See our complete notes on Shire at:
IPXL: 31.42 (-0.05), AVXL: 3.84 (+0.33), SHPG: 194.12 (+2.69), NVS: 83.26 (+1.18)
Company News for July 13, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 9:10AM CDT
Companies In The News are: RRD,XRX,SHPG,FAST,BX
FAST: 42.75 (+0.25), BX: 26.84 (-0.15), SHPG: 194.12 (+2.69), XRX: 10.30 (+0.39), RRD: 17.92 (+0.14)
Multimedia assets now available: FDA Approves Shire's Xiidra(TM) (lifitegrast ophthalmic solution) 5% - The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
PR Newswire - Tue Jul 12, 7:44PM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the U.S. Food and Drug Administration (FDA) has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition. Shire expects to launch Xiidra in the United States in the third quarter of 2016.
SHPG: 194.12 (+2.69)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Regulatory Approval - FDA Approves Shire's Xiidra(TM) (lifitegrast ophthalmic solution) 5% - The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
PR Newswire Europe - Mon Jul 11, 6:09PM CDT
LEXINGTON, Massachusetts, July 11, 2016 /PRNewswire/ --
SHPG: 194.12 (+2.69)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Shire Receives Extension of Market Authorization in Europe for Revestiveâ-¼ (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
PR Newswire - Thu Jul 07, 1:00AM CDT
This press release is intended for a global audience.
SHPG: 194.12 (+2.69)
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:19PM CDT
Shire plc (SHPG) announced that it will license global rights to all indications of Pfizer's candidate, PF-00547659.
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the Treatment of Emphysema Due To Severe AAT Deficiency
PR Newswire - Wed Jun 15, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) and Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)], marking the first treatment for adult patients with emphysema due to severe Alpha-1 Antitrypsin (AAT) Deficiency that can be self-infused at home after appropriate training.
SHPG: 194.12 (+2.69), KMDA: 3.96 (unch)
Shire Gets Breakthrough Status for Rare Disease Candidates
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:18PM CDT
Shire plc (SHPG) announced that the FDA has granted Breakthrough Therapy Designation to two candidates in its rare diseases pipeline.
ABT: 44.75 (+0.30), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22), BMY: 74.81 (+0.15)
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
PR Newswire Europe - Fri Jun 10, 2:12PM CDT
ZUG, Switzerland, June 10, 2016 /PRNewswire/ --
SHPG: 194.12 (+2.69)
Shire Recommends ADS Holders Reject TRC Capital's "Mini-Tender Offer"
PR Newswire - Fri Jul 29, 3:20PM CDT
Shire plc (LSE: SHP) (NASDAQ: SHPG) has been notified of an unsolicited "mini-tender" offer made by TRC Capital Corporation ("TRC Capital"
to purchase up to 1,000,000 American Depositary Shares ("ADSs" of Shire, each representing three ordinary shares of Shire, at a price of $182.75 per ADS in cash. The offer is for approximately 0.33 percent of the outstanding ordinary shares of Shire. SHPG: 194.12 (+2.69)
Shire's SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
PR Newswire Europe - Fri Jul 29, 6:01AM CDT
LEXINGTON, Massachusetts, July 29, 2016 /PRNewswire/ --
SHPG: 194.12 (+2.69)
ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia
PR Newswire - Tue Jul 26, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) will present additional data on the clinical experience of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant Factor VIII (rFVIII) replacement for hemophilia A, during the International Congress of the World Federation of Hemophilia (WFH) in Orlando, Florida. Throughout the Congress, Shire will present more than a dozen scientific updates on the company's broad portfolio of treatments for bleeding disorders, including ADYNOVATE.
SHPG: 194.12 (+2.69)
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
PR Newswire Europe - Mon Jul 25, 1:01AM CDT
ZUG, Switzerland, July 25, 2016 /PRNewswire/ --
MACK: 5.80 (+0.19), SHPG: 194.12 (+2.69)
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union
PR Newswire - Mon Jul 25, 1:01AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for ONIVYDE® (irinotecan liposome injection), also known as "nal-IRI", in combination with fluorouracil (5-FU) and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma who have progressed after gemcitabine-based therapy. The CHMP positive opinion for ONIVYDE will now be reviewed by the European Commission (EC) for marketing authorization. Shire plc (LSE: SHP, NASDAQ: SHPG) is responsible for the development and commercialization of ONIVYDE outside of the United States and Taiwan pursuant to an exclusive licensing agreement with Merrimack.
MACK: 5.80 (+0.19), SHPG: 194.12 (+2.69)
Shire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of the World Federation of Hemophilia
PR Newswire - Tue Jul 19, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG), following its combination with Baxalta in June, will affirm its commitment to advancing patient care and scientific innovation at the International Congress of the World Federation of Hemophilia (WFH) in Orlando, Florida, July 24-28, 2016. Data at the Congress this year will showcase the company's robust hematology portfolio and pipeline.
SHPG: 194.12 (+2.69)
Coverage Initiated on Select Healthcare Stocks
ACCESSWIRE - Thu Jul 14, 8:17AM CDT
LONDON, UK / ACCESSWIRE / July 14, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Healthcare sector. Companies recently under review include Shire, Novartis, Anavex Life Sciences, and Impax Laboratories. See our complete notes on Shire at:
IPXL: 31.42 (-0.05), AVXL: 3.84 (+0.33), SHPG: 194.12 (+2.69), NVS: 83.26 (+1.18)
Company News for July 13, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 9:10AM CDT
Companies In The News are: RRD,XRX,SHPG,FAST,BX
FAST: 42.75 (+0.25), BX: 26.84 (-0.15), SHPG: 194.12 (+2.69), XRX: 10.30 (+0.39), RRD: 17.92 (+0.14)
Multimedia assets now available: FDA Approves Shire's Xiidra(TM) (lifitegrast ophthalmic solution) 5% - The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
PR Newswire - Tue Jul 12, 7:44PM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the U.S. Food and Drug Administration (FDA) has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition. Shire expects to launch Xiidra in the United States in the third quarter of 2016.
SHPG: 194.12 (+2.69)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Regulatory Approval - FDA Approves Shire's Xiidra(TM) (lifitegrast ophthalmic solution) 5% - The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
PR Newswire Europe - Mon Jul 11, 6:09PM CDT
LEXINGTON, Massachusetts, July 11, 2016 /PRNewswire/ --
SHPG: 194.12 (+2.69)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Shire Receives Extension of Market Authorization in Europe for Revestiveâ-¼ (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
PR Newswire - Thu Jul 07, 1:00AM CDT
This press release is intended for a global audience.
SHPG: 194.12 (+2.69)
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:19PM CDT
Shire plc (SHPG) announced that it will license global rights to all indications of Pfizer's candidate, PF-00547659.
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the Treatment of Emphysema Due To Severe AAT Deficiency
PR Newswire - Wed Jun 15, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) and Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)], marking the first treatment for adult patients with emphysema due to severe Alpha-1 Antitrypsin (AAT) Deficiency that can be self-infused at home after appropriate training.
SHPG: 194.12 (+2.69), KMDA: 3.96 (unch)
Shire Gets Breakthrough Status for Rare Disease Candidates
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:18PM CDT
Shire plc (SHPG) announced that the FDA has granted Breakthrough Therapy Designation to two candidates in its rare diseases pipeline.
ABT: 44.75 (+0.30), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22), BMY: 74.81 (+0.15)
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
PR Newswire Europe - Fri Jun 10, 2:12PM CDT
ZUG, Switzerland, June 10, 2016 /PRNewswire/ --
SHPG: 194.12 (+2.69)
